Información del artículo
Abstract
Introduction
Stroke and atrial fibrillation (AF) are a real vascular epidemic, and the consequences are disastrous. The most common complication of AF is stroke.
BackgroundThe correct aetiological diagnosis of stroke is essential for adequate prevention. The percentage of cryptogenic ischaemic strokes is far too high and the detection of AF needs to be improved. Cardio-embolic cerebral ischaemia due to AF is preventable, however due to medical inertia, the lack of compliance by the patient, and the problems with oral vitamin K antagonist anticoagulants, means that many patients with AF are at risk of suffering from a stroke.
ConclusionsThe significant recent advances with drugs such as dronedarone and dabigatran, provide real hope for an improvement in its prevention, and for this reason neurologists must know about them.
Keywords:
Stroke
Atrial fibrillation
Prevention
Dronedarone
Dabigatran
Resumen
Introducción
El ictus y la fibrilación auricular (FA) son una verdadera epidemia vascular, y sus consecuencias son catastróficas. La complicación más común y devastadora de la FA es el ictus.
DesarrolloEl diagnóstico etiológico correcto del ictus es esencial para poder realizar una prevención adecuada. El porcentaje de ictus isquémicos criptogénicos es demasiado elevado, y es preciso mejorar la detección de la FA. La isquemia cerebral cardioembólica por FA es prevenible, pero la inercia médica, la falta de adherencia del paciente y los problemas de los anticoagulantes orales antagonistas de la vitamina K hacen que muchos pacientes con FA estén en riesgo de sufrir una isquemia cerebral.
ConclusionesLos relevantes avances recientes con fármacos como la dronedarona y el dabigatrán abren una esperanza real para mejorar su prevención y pronto se reflejarán en las guías terapéuticas de prevención y, por lo tanto, los neurólogos debemos conocerlos.
Palabras clave:
Ictus
Fibrilación auricular
Prevención
Dronedarona
Dabigatrán
El Texto completo está disponible en PDF
References
[1.]
Defunciones según causa de muerte. Available at: www.ine.es, 6 Abril 2009.
[2.]
J.M. Beguiristain, J. Mar, A. Arrazola.
Coste de la enfermedad cerebrovascular aguda.
Rev Neurol, 40 (2005), pp. 406-411
[3.]
G.E. Gresham, M. Kelly-Hayes, P.A. Wolf, et al.
Survival and functional status 20 or more years after stroke: The Framingham Study.
Stroke, 29 (1998), pp. 793-797
[4.]
Encuesta de Morbilidad Hospitalaria. Available at: www.ine.es, 28 December 2009.
[5.]
B.N. Singh.
Recent advances in the management of atrial fibrillation.
Eur Heart J Suppl, 10 (2008), pp. H2-H3
[6.]
A.S. Go, E.M. Hylek, K.A. Philips, Y. Chang, L.E. Henault, J.V. Selby, et al.
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention; the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
JAMA, 285 (2001), pp. 2370-2375
[7.]
D.M. Lloyd-Jones, T.J. Wang, E.P. Leip, M.G. Larson, D. Levy, R.S. Vasan, et al.
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.
Circulation, 110 (2004), pp. 1042-1046
[8.]
R.L. Sacco, J.H. Ellenberg, J.P. Mohr, et al.
Infarcts of undetermined cause: the NINCDS Stroke Data Bank.
Ann Neurol, 25 (1989), pp. 382-390
[9.]
R. Nieuwlaat, M.H. Prins, J.Y. Le Heuzey, P.E. Vardas, E. Aliot, M. Santini, et al.
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation.
Eur Heart J, 29 (2008), pp. 1181-1189
[10.]
P.A. Wolf, R.D. Abbott, W.B. Kannel.
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
Stroke, 22 (1991), pp. 983-988
[11.]
S. Penado, M. Cano, O. Acha, J.L. Hernández, J.A. Riancho.
Atrial fibrillation as a risk factor for stroke recurrence.
Am J Med, 114 (2003), pp. 206-210
[12.]
C. Marini, F. De Santis, S. Sacco, T. Russo, L. Olivieri, R. Totaro, et al.
Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study.
Stroke, 36 (2005), pp. 1115-1119
[13.]
I. Savelieva, A. Bajpai, A.J. Camm.
Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
Ann Med, 39 (2007), pp. 371-391
[14.]
P.L. Kolominsky-Rabas, M. Weber, O. Gefeller, B. Neundoerfer, P.U. Heuschmann.
Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study.
Stroke, 32 (2001), pp. 2735-2740
[15.]
G.W. Petty, B.K. Khandheria, J.P. Whisnant, J.D. Sicks, W.M. O’Fallon, D.O. Wiebers.
Predictors of cerebrovascular events and death among patients with valvular heart disease: A population-based study.
Stroke, 31 (2000), pp. 1062-1068
[16.]
D.A. Dulli, H. Stanko, R.L. Levine.
Atrial fibrillation is associated with severe acute ischemic stroke.
Neuroepidemiology, 22 (2003), pp. 118-123
[17.]
R.L. Page, T.W. Tilsch, S.J. Connolly, D.J. Schnell, S.R. Marcello, W.E. Wilkinson, et al.
Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or “silent” atrial fibrillation: frequency in untreated patients and patients receiving azimilide.
Circulation, 107 (2003), pp. 1141-1145
[18.]
A.S. Go.
The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg.
Am J Geriatr Cardiol, 14 (2005), pp. 56-61
[19.]
A. Gil-Núñez, J. Vivancos, R. Gabriel.
Proyecto Ictus del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología. Diagnosis and secondary prevention measures in patients hospitalized for cerebral infarction in Spain. The DIAPRESIC study.
Med Clin (Barc), 131 (2008), pp. 765-769
[21.]
D. Rigau Comas, J. Alvarez-Sabin, A. Gil Núñez, S. Abilleira Castells, F.X. Borras Pérez, P. Armario García, et al.
Primary and secondary prevention of stroke: A guideline.
Med Clin (Barc), 133 (2009), pp. 754-762
[22.]
E.H. Yu, C. Lungu, R.M. Kanner, R.B. Libman.
The use of diagnostic tests in patients with acute ischemic stroke.
J Stroke Cerebrovasc Dis, 18 (2009), pp. 178-184
[23.]
A.H. Tayal, M. Tian, K.M. Kelly, S.C. Jones, D.G. Wrigth, D. Singh, et al.
Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke.
Neurology, 71 (2008), pp. 1696-1701
[24.]
J. Liao, Z. Khalid, C. Scallan, C. Morillo, M. O’Donnell.
Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke. A systematic review.
Stroke, 38 (2007), pp. 2935-2940
[25.]
J. Díaz-Guzmán, J.A. Egido-Herrero, B. Fuentes, C. Fernández-Pérez, R. Gabriel-Sánchez, G. Barberà, et al.
Proyecto Ictus del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología. Incidence of strokes in Spain: the Iberictus study. Data from the pilot study.
Rev Neurol, 48 (2009), pp. 61-65
[26.]
V. Fuster, L.E. Rydén, D.S. Cannom, H.J. Crijns, A.B. Curtis, K.A. Ellenbogen, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
Circulation, 114 (2006), pp. e257-e354
[27.]
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Lancet, 342 (1993), pp. 1255-1262
[28.]
R.G. Hart, L.A. Pearce, M.I. Aguilar.
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
Ann Intern Med, 146 (2007), pp. 857-867
[29.]
E. Díez Tejedor, B. Fuentes, A.C. Gil Núñez, A. Gil Peralta, J. Matias Guiu.
por el comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN. Guía para el tratamiento preventivo de la isquemia cerebral.
Guía para el tratamiento y la prevención del ictus,
[30.]
R.L. Sacco, R. Adams, G. Albers, M.J. Alberts, O. Benavente, K. Furie, American Heart Association; American Stroke Association Council on Stroke. Council on Cardiovascular Radiology and Intervention; American Academy of Neurology, et al.
Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.
Stroke, 37 (2006), pp. 577-617
[31.]
European Stroke Organisation (ESO) Executive Committee.
ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.
Cerebrovasc Dis, 25 (2008), pp. 457-507
[32.]
F. Pérez-Gómez, E. Alegría, J. Berjón, J.A. Iriarte, J. Zumalde, A. Salvador, et al.
NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
J Am Coll Cardiol, 44 (2004), pp. 1557-1566
[33.]
D.G. Sherman.
Stroke prevention in atrial fibrillation: pharmacological rate versus rhythm control.
Stroke, 38 (2007), pp. 615-617
[34.]
D.G. Wyse, A.L. Waldo, J.P. DiMarco, M.J. Domanski, Y. Rosenberg, E.B. Schron, et al.
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation.
N Engl J Med, 347 (2002), pp. 1825-1833
[35.]
D. Roy, M. Talajic, S. Nattel, D.G. Wyse, P. Dorian, K.L. Lee, et al.
Rhythm control versus rate control for atrial fibrillation and heart failure.
N Engl J Med, 358 (2008), pp. 2667-2677
[36.]
R.G. Hart, M.I. Aguilar.
Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage.
J Thromb Thrombolysis, 25 (2008), pp. 26-32
[37.]
A. Odén, M. Fahlén, R.G. Hart.
Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal.
Thromb Res, 117 (2006), pp. 493-499
[38.]
G.P. Samsa, D.B. Matchar, L.B. Goldstein, A.J. Bonito, L.J. Lux, D.M. Witter, et al.
Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities.
Arch Intern Med, 160 (2000), pp. 967-973
[39.]
P. Laguna, A. Martn, C. Del Arco, P. Gargantilla, Investigators in the Spanish Atrial Fibrillation in Emergency Medicine Study Group (GEFAUR).
Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study.
Ann Emerg Med, 44 (2004), pp. 3-11
[40.]
D.J. Gladstone, E. Bui, B. Fang, A. Laupacis, M.P. Lindsay, J.V. Tu, et al.
Potentially preventable strokes in high risk patients with atrial fibrillation who are not adequately anticoagulated.
Stroke, 40 (2009), pp. 235-240
[41.]
S.J. Connolly, J. Pogue, J. Eikelboom, et al.
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.
Circulation, 118 (2008), pp. 2029-2037
[42.]
E.V. Glader, M. Sjölander, M. Eriksson, M. Lundberg.
Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke.
Stroke, 41 (2010), pp. 397-401
[43.]
E.M. Hylek, C. Evans-Molina, C. Shea, L.E. Henault, S. Regan.
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
Circulation, 115 (2007), pp. 2689-2696
[44.]
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.
Analysis of pooled data from five randomized controlled trials.
Arch Intern Med, 154 (1994), pp. 1449-1457
[45.]
F.D.R. Hobbs, C. Van Walraven, R.G. Hart, S. Connolly, P.C. Austin, J. Jonathan Mant, et al.
Effect of age on stroke prevention therapy in patients with atrial fibrillation: The Atrial Fibrillation Investigators.
Stroke, 40 (2009), pp. 1410-1416
[46.]
D.E. Singer, Y. Chang, M.C. Fang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, et al.
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
Ann Intern Med, 151 (2009), pp. 297-305
[47.]
J. Mant, F.D. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice, G.Y. Lip, BAFTA investigators. Midland Research Practices Network (MidReC), et al.
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.
Lancet, 370 (2007), pp. 493-503
[48.]
M. O’Donnell, W. Oczkowski, J. Fang, C. Kearon, J. Silva, C. Bradley, et al.
Investigators of the Registry of the Canadian Stroke Network. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study.
Lancet Neurol, 5 (2006), pp. 749-754
[49.]
N.M. Allen LaPointe, L. Governale, J. Watkins, J. Mulgund, K.J. Anstrom.
Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation.
Am Heart J, 154 (2007), pp. 893-898
[50.]
K. Lakshimarayan, C.A. Solid, A.J. Collins, D.C. Anderson, C.A. Herzog.
Atrial fibrillation and stroke in the general medicare population: a 10 year perspective.
Stroke, 37 (2006), pp. 1969-1974
[51.]
S.H. Hohnloser, H.J.G.M. Crijns, M. Van Eickels, C. Gaudin, R.L. Page, C. Torp-Pedersen, et al.
Effect of dronedarone on cardiovascular events in atrial fibrillation.
N Engl J Med, 360 (2009), pp. 668-678
[52.]
S.J. Connolly, H.J. Crijns, C. Torp-Pedersen, M. Van Eickels, C. Gaudin, R.L. Page, et al.
ATHENA Investigators. Analysis of stroke in ATHENA: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
Circulation, 120 (2009), pp. 1174-1180
[53.]
G. Patti, M. Chello, D. Candura, V. Pasceri, A. D’Ambrosio, E. Covino, et al.
Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.
Circulation, 114 (2006), pp. 1455-1461
[54.]
L. Fauchier, B. Pierre, A. De Labriolle, C. Grimard, N. Zannad, D. Babuty.
Antiarrhythmic effect of statin therapy and atrial fibrillation –a meta-analysis of randomized controlled trials.
J Am Coll Cardiol, 51 (2008), pp. 828-835
[55.]
G. Casaclang-Verzosa, B.J. Gersh, T.S.M. Tsang.
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.
J Am Coll Cardiol, 51 (2008), pp. 1-11
[56.]
F. Belluzzi, L. Sernesi, P. Preti, F. Salinaro, M.L. Fonte, S. Perlini.
Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.
J Am Coll Cardiol, 53 (2009), pp. 24-29
[57.]
B.A. Schaer, C. Schneider, S.S. Jick, D. Conen, S. Osswald, C.R. Meier.
Risk for incident AF in patients who receive antihypertensive drugs.
Ann Intern Med, 152 (2010), pp. 78-84
[58.]
O. Onalan, E. Eugene Cristal.
Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation.
Stroke, 38 (2007), pp. 624-630
[59.]
D.R. Holmes, V.Y. Reddy, Z.G. Turi, S.K. Doshi, H. Sievert, M. Buchbinder, et al.
for the PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
Lancet, 374 (2009), pp. 534-542
[60.]
The ACTIVE Investigators.
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
N Engl J Med, 360 (2009), pp. 2066-2078
[61.]
S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, et al.
the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.
N Engl J Med, 361 (2009), pp. 1139-1151
[62.]
Diener HC, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Reilly PA, et al; the RE-LY Steering Committee Investigators. Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: Results of RE-LY. American Stroke Association/International Stroke Conference 2010; February 26, 2010; San Antonio,TX.
[63.]
G.J. Hankey, J.W. Eikelboom.
Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.
Lancet Neurol, 9 (2010), pp. 273-294
Copyright © 2010. Sociedad Española de Neurología
